Matches in Wikidata for { <http://www.wikidata.org/entity/Q63397910> ?p ?o ?g. }
Showing items 1 to 36 of
36
with 100 items per page.
- Q63397910 description "clinical trial" @default.
- Q63397910 description "ensayu clínicu" @default.
- Q63397910 description "klinisch onderzoek" @default.
- Q63397910 description "клінічне випробування" @default.
- Q63397910 name "Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" @default.
- Q63397910 type Item @default.
- Q63397910 label "Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" @default.
- Q63397910 prefLabel "Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis" @default.
- Q63397910 P1050 Q63397910-AD6AAE32-FD55-47DD-98DD-2EC3B503D372 @default.
- Q63397910 P1132 Q63397910-04C130BB-8CCB-47CB-A721-647D5BBA6135 @default.
- Q63397910 P1476 Q63397910-93DD1544-0223-4A23-8244-9F92168CCD35 @default.
- Q63397910 P17 Q63397910-346FAA85-DB64-46A4-886E-291616C7F8B1 @default.
- Q63397910 P2899 Q63397910-E997E89A-EBA5-4B2B-B4F5-278728CDE270 @default.
- Q63397910 P3098 Q63397910-E932C42C-494C-4192-B9DA-9DD98D61E285 @default.
- Q63397910 P31 Q63397910-F3866B2D-6548-42ED-986F-06F490E942E0 @default.
- Q63397910 P580 Q63397910-7A8B6146-299B-4A9F-87AD-7E154E8DE123 @default.
- Q63397910 P582 Q63397910-06C49F1A-6BF4-4BBC-99AA-702119F904CC @default.
- Q63397910 P6099 Q63397910-21EE9357-A817-4633-9045-916DD9876A67 @default.
- Q63397910 P6153 Q63397910-3EAED65C-8D2B-492A-8675-C50E8D5BA251 @default.
- Q63397910 P8363 Q63397910-F5B5AF10-B964-4BB7-B95D-7663F0795CFE @default.
- Q63397910 P859 Q63397910-B42FF907-D20E-4BCC-87C6-E93F87B5FA7B @default.
- Q63397910 P921 Q63397910-5FCE2690-6A12-4537-98BF-00C49E406016 @default.
- Q63397910 P1050 Q179945 @default.
- Q63397910 P1132 "+330" @default.
- Q63397910 P1476 "A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis" @default.
- Q63397910 P17 Q30 @default.
- Q63397910 P2899 "+18" @default.
- Q63397910 P3098 "NCT03504852" @default.
- Q63397910 P31 Q30612 @default.
- Q63397910 P580 "2018-06-25T00:00:00Z" @default.
- Q63397910 P582 "2021-03-25T00:00:00Z" @default.
- Q63397910 P6099 Q42824827 @default.
- Q63397910 P6153 Q507154 @default.
- Q63397910 P8363 Q78089383 @default.
- Q63397910 P859 Q507154 @default.
- Q63397910 P921 Q7444755 @default.